Conditions: Malignant Neoplasms of Thyroid and Other Endocrine Glands; Anaplastic Thyroid Carcinoma; Poorly Differentiated Thyroid Cancer
Interventions: Drug: Nab-paclitaxel - INDUCTION COHORT; Drug: Paclitaxel - INDUCTION COHORT; Drug: Vemurafenib - COHORT 1; Drug: Cobimetinib - COHORT 1; Drug: Atezolizumab - COHORT 1; Drug: Bevacizumab - COHORT 3; Drug: Nab-paclitaxel - COHORT 4; Drug: Paclitaxel - COHORT 4; Drug: Cobimetinib - COHORT 2; Drug: Atezolizumab - COHORT 2; Drug: Atezolizumab - COHORT 3; Drug: Atezolizumab - COHORT 4
Sponsors: M.D. Anderson Cancer Center; Genentech, Inc.
Not yet recruiting - verified June 2017
http://ift.tt/2rZvJXL
Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,alsfakia@gmail.com,
Ετικέτες
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Ειδοποίηση Μελετητή:[ ωτα ] [HTML] Gender, identity and material: Film screening C Brand - 2017 ftypM4V *M4V M4A mp42isom*a┌moovlmvhd...
-
Publication date: September 2017 Source: Free Radical Biology and Medicine, Volume 110 Author(s): Lucía Fernández-del-Río, Anish Nag, Elen...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου